However, the current study clearly demonstrates that while this dose of LIRA prevents cardiomyocyte enlargement by inhibiting ET-1, OPN and TGF-β signaling (Figs. 7 and 8), it was not sufficient to normalize heart mass at the end of the treatment period in these young adult male rats with metabolic syndrome. Here, EDN1 is linked to metabolic syndrome.